UPDATE 1-Dynavax to raise $44 mln from public offering

* Says will use proceeds to further advance Heplisav

* Says 30,293,000 units are being sold at $1.4525/unit

April 13 (BestGrowthStock) – Dynavax Technologies Corp (DVAX.O: )
said it would raise $44 million from a public offering of
common stocks and warrants.

The biopharmaceutical company, which will use the proceeds
for development of its experimental hepatitis B vaccine
Heplisav, said it was offering about 30.3 million units at a
price of $1.4525 per unit.

Each unit consisted of one share of common stock and one
warrant to purchase 0.5 of a common share.

The warrants have a term of five years and an exercise
price of $1.50 per share.

The offering, managed by Wedbush PacGrow LifeSciences, is
expected to close by April 16.

Shares of the company closed at $1.39 Monday on Nasdaq.

Investment Advice

(Reporting by Krishnakali Sengupta in Bangalore; Editing by
Don Sebastian)

UPDATE 1-Dynavax to raise $44 mln from public offering